CSPC Pharmaceutical Group Ltd. has announced that its recombinant fully human anti-βKlotho monoclonal antibody drug, JMT202, has received approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the United States. This drug, an FGFR1c/βKlotho receptor agonist, is designed to regulate glycolipid metabolism and has potential applications in treating metabolism-related diseases such as dyslipidemia, metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes, and obesity. The clinical trial will focus on hypertriglyceridemia $(HTG.UK)$. JMT202 has previously obtained approval from the National Medical Products Administration of China and is undergoing trials in China. Preclinical studies have shown that the drug has a favorable safety profile and can significantly reduce triglyceride levels, suggesting promising clinical development potential.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。